China Biopharmaceutical (01177): The latest research results on TQ-A3334 “TLR7 agonist” and Bepirovirsen “ASO” will be announced in 2026 AASLD

Zhitongcaijing · 2d ago

Zhitong Finance App News, China Biopharmaceutical (01177) announced that the results of a clinical study of the national Class 1 innovative drug TQ-A3334 (TLR7 agonist) independently developed by Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), a subsidiary of the Group, have been selected for the latest breakthrough summary (LBA) of the 2026 American Society for Liver Disease Research (AASLD) Annual Meeting (LBA), and will be announced in the form of an oral report; Zhengda Tianqing and GlaxoSmithKline (GSK) strategic cooperation products Bepirovirsen (ASO) was selected for 2 oral presentations and 8 poster presentations (including 1 excellent poster).